MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow MNKD
MannKind Corporation (MNKD) P/E ratio
MannKind Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 280× (February 2026) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 255× | 307.54% |
| FY2024 | 62.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 2.6× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 255× | 386.08% |
| Sep 2025 | 52.5× | 57.63% |
| 36 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMTX Immatics N.V. compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. compare | n/m |
| MNKD MannKind Corporation | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SVRA Savara Inc. compare | n/m |
| MGTX MeiraGTx Holdings PLC compare | 12.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)